Immunome ( (IMNM) ) has shared an announcement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunome, Inc. has secured a pivotal asset purchase from Zentalis Pharmaceuticals, acquiring a license for innovative antibody-drug conjugate technology. This strategic move involves issuing shares to Zentalis and a potential $5 million payment upon reaching a developmental milestone. A stock issuance agreement includes restrictions on Zentalis’s trading activities, ensuring stability in Immunome’s stock performance. While forward-looking statements suggest potential growth, investors should remain aware of inherent risks and uncertainties.
For detailed information about IMNM stock, go to TipRanks’ Stock Analysis page.